Effect of Trastuzumab and Lonidamine-Loaded Lipid Nanoparticles (LNP) on HER2+Breast Cancer

Our study involves inhibition of glycolysis and inhibition of the HER2 pathway, which is highly expressed in many types of cancer. Decreased survival, negative metastasis, and induced apoptosis are expected due to the combined inhibition of these two targets. Trastuzumab was used as the HER2 inhibitor and lonidamine was used as the HK2 inhibitor. Lonidamine (LND) was delivered to cells as hybrid nanoparticles to enhance the effect of lonidamine and make it target specific. Separate cytotoxicity studies were conducted for LND, LND-NP and Tmab. While application of lonidamine alone gave an IC50 value of 124.6 mu M, application in NP reduced the IC50 value to 44.18 mu M. In addition, the combination of Tmab and LND-NP showed synergistic effects compared to treatments alone in other analyses. On the aspect of apoptosis, this combination showed a 14-fold increased apoptosis compared to the control group. This combination therapy can prevent drug resistance. In addition, the hybrid nanoparticle structure used will prevent the formation of toxicity as it will ensure that LND is administered to the body with less repetition. Our study aims to minimize the negative effects of the chemotherapy process by improving it with various variations in future studies. Targeting two separate pathways simultaneously produced a synergistic effect. According to the analyses, the combination of trastuzumab and lonidamine-loaded lipid nanoparticles caused significantly increased apoptosis. Our study showed that combined treatment is more effective than single drug administration in breast cancer. image